The effect of effervescent and buffered alendronate on bone turnover compared to conventional alendronate: A randomized non-inferiority trial
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Alendronic acid (Primary)
- Indications Metabolic bone diseases
- Focus Therapeutic Use
- 02 Nov 2022 Status changed from recruiting to completed.
- 19 May 2021 New trial record